Deal record
2018 · Growth Investment
KKR investment in Impel Pharmaceuticals
Late-stage biopharmaceutical company that optimizes drug delivery for central nervous system diseases using its proprietary nasal drug delivery technology
Research completeness
80out of 100
Deep Record
A completeness measure, not an investment score. Core coverage measures identity, ownership, chronology, classification, company facts, sources and review status. Transaction announcements can also earn depth from disclosed people, providers, value, completion evidence and structured findings.
1 source0 named people0 provider roles0 research signalsValue not disclosedCompletion date not established
Transaction facts
- Investment year
- 2018
- Evidence level
- Official Portfolio Record
- Status
- Completed
- Transaction type
- Growth Investment
- Seller
- Not established
Publicly disclosed provider roles
No provider role has been added from the reviewed public sources.
Named transaction professionals
No individual transaction attribution has been added from the reviewed public sources.